Aventis, Baxter Renew Battle Over Hemophilia Drug

Law360, New York (October 18, 2006, 12:00 AM EDT) -- Aventis Pharma SA has refiled a lawsuit claiming Baxter Healthcare Corp. markets a drug that infringes its patent related to Factor VIII, the protein necessary to form blood clots.

In the suit, which was filed Monday in the U.S. District Court in Wilmington, Del., Aventis said that Baxter’s hemophilia drug Advate contained a stabilized solution with Factor VIII activity.

The patent was originally granted in 1996 to what, after many mergers, would become Aventis.

Eventually, it became known that Baxter, a subsidiary of Baxter International Inc.,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.